GTx/Merck SARM Demonstrates Muscle Improvements In Cancer Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II trial evaluating Ostarine in patients with cancer-induced muscle loss meets its primary endpoint.
You may also be interested in...
GTx Files Toremifene For Prostate Cancer-Related Bone Loss
Biopharma is seeking a priority review for 80 mg toremifene, already marketed as Fareston at a 60 mg dose for breast cancer.
GTx Files Toremifene For Prostate Cancer-Related Bone Loss
Biopharma is seeking a priority review for 80 mg toremifene, already marketed as Fareston at a 60 mg dose for breast cancer.
GTx Continues Phase III For Toremifene 20 Mg With Goal Of 2009 NDA
Bar is lower for meeting primary efficacy endpoint at trial’s end than for interim data review, firm tells “The Pink Sheet” DAILY.